Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TELO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTelomir receives FDA clearance to begin human trials of lead cancer drug Telomir-Zn
Filed April 30, 2026 · Period ending April 24, 2026 · ~1 min read
Key Changes
-
high
FDA cleared IND application for Telomir-Zn in advanced triple-negative breast cancer, enabling first human trials of the company's lead drug candidate
Item 8.01 verify on EDGAR → -
high
Phase 1/2 trial to enroll ~76 patients starting first half 2026, with Phase 1 establishing safe dosing and Phase 2 measuring tumor response rates
Item 8.01 verify on EDGAR → -
high
Primary Phase 2 endpoint is objective response rate (ORR), with secondary measures including progression-free survival, overall survival, and duration of response
Item 8.01 verify on EDGAR → -
medium
Phase 1 will assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity while determining optimal dosing for expansion phase
Item 8.01 verify on EDGAR →
Summary
Telomir Pharmaceuticals announced a significant regulatory milestone: FDA clearance of its Investigational New Drug application for Telomir-Zn, the company's lead therapeutic candidate targeting advanced or metastatic triple-negative breast cancer.
This clearance removes a critical regulatory hurdle and allows Telomir to begin its first human clinical trials, representing the transition from preclinical development to proof-of-concept testing in patients. The planned Phase 1/2 study will enroll approximately 76 patients across two stages.
The initial Phase 1 portion focuses on establishing safety and identifying the right dose, while Phase 2 will provide the first meaningful data on whether Telomir-Zn can shrink tumors in this difficult-to-treat cancer type. Triple-negative breast cancer lacks targeted treatment options, making it an area of high unmet medical need. For investors, the key near-term catalyst is trial initiation in the first half of 2026. Watch for announcements about the first patient dosed and, later in 2026 or early 2027, preliminary safety data from Phase 1. Success in demonstrating acceptable safety and any early efficacy signals would significantly de-risk the program and potentially drive partnership interest.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The planned Phase 1/2 study is expected to enroll approximately 76 patients and will consist of a dose-escalation Phase 1 portion followed by a dose-expansion Phase 2 portion.
The company plans a two-part clinical trial enrolling about 76 patients. Phase 1 will establish safe dosing and Phase 2 will evaluate preliminary efficacy, representing the first human testing of Telomir-Zn.
Added in current filing · verify on EDGAR →
The Phase 1 portion of the study is designed to evaluate safety, tolerability, dose-limiting toxicities, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity, and to determine the maximum tolerated dose and recommended Phase 2 dose.
Phase 1 will assess safety, tolerability, and how the drug behaves in the body, while also looking for early signs of anti-tumor activity. The goal is to identify the optimal dose for the Phase 2 expansion.
Added in current filing · verify on EDGAR →
The Phase 2 portion of the study is designed to evaluate preliminary efficacy, with the objective response rate (ORR) as the primary endpoint. Secondary endpoints include duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.
Phase 2 will measure how many patients respond to treatment (ORR) as the main outcome, along with how long responses last, how long patients live without disease progression, overall survival, and continued safety monitoring.
Added in current filing · verify on EDGAR →
The Company plans to initiate the Phase 1/2 clinical trial in the first half of 2026, subject to standard clinical and operational considerations.
Telomir expects to start enrolling patients in the first half of 2026, pending normal clinical trial startup activities. This provides a near-term catalyst for investors tracking the company's development progress.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify